Patients with type 1 diabetes mellitus and recommended low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B targets – a SwissDiab study - Scorecard - MDSpire
Advertisement
Patients with type 1 diabetes mellitus and recommended low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B targets – a SwissDiab study
Clinical Scorecard: Lipid Management Targets in Type 1 Diabetes Mellitus Patients: Insights from the SwissDiab Study on LDL, Non-HDL, and Apolipoprotein B Levels
At a Glance
Category
Detail
Condition
Key Mechanisms
Hyperlipidemia as a modifiable driver of atherosclerotic cardiovascular disease (ASCVD) - ensure sourced.
Target Population
Care Setting
Key Highlights
Remove phrases suggesting implications or conclusions not directly supported by the source.
Guideline-Based Recommendations
Diagnosis
Management
S
p
e
c
i
f
y
t
h
a
t
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
a
r
e
b
a
s
e
d
o
n
t
h
e
2
0
2
1
E
u
r
o
p
e
a
n
S
o
c
i
e
t
y
o
f
C
a
r
d
i
o
l
o
g
y
g
u
i
d
e
l
i
n
e
s
.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
216 adult patients with T1DM
Low prescription rates of lipid-lowering therapy despite high cardiovascular risk
Clinical Best Practices
Remove any interpretations or recommendations not directly stated in the source.
A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.
